Literature DB >> 23680635

D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms.

Lani S Chun1, R Benjamin Free, Trevor B Doyle, Xi-Ping Huang, Michele L Rankin, David R Sibley.   

Abstract

The D(1) dopamine receptor (D(1)R) has been proposed to form a hetero-oligomer with the D(2) dopamine receptor (D(2)R), which in turn results in a complex that couples to phospholipase C-mediated intracellular calcium release. We have sought to elucidate the pharmacology and mechanism of action of this putative signaling pathway. Dopamine dose-response curves assaying intracellular calcium mobilization in cells heterologously expressing the D(1) and D(2) subtypes, either alone or in combination, and using subtype selective ligands revealed that concurrent stimulation is required for coupling. Surprisingly, characterization of a putative D(1)-D(2) heteromer-selective ligand, 6-chloro-2,3,4,5-tetrahydro-3-methyl-1-(3-methylphenyl)-1H-3-benzazepine-7,8-diol (SKF83959), found no stimulation of calcium release, but it did find a broad range of cross-reactivity with other G protein-coupled receptors. In contrast, SKF83959 appeared to be an antagonist of calcium mobilization. Overexpression of G(qα) with the D(1) and D(2) dopamine receptors enhanced the dopamine-stimulated calcium response. However, this was also observed in cells expressing G(qα) with only the D1R. Inactivation of Gi or Gs with pertussis or cholera toxin, respectively, largely, but not entirely, reduced the calcium response in D(1)R and D(2)R cotransfected cells. Moreover, sequestration of G(βγ) subunits through overexpression of G protein receptor kinase 2 mutants either completely or largely eliminated dopamine-stimulated calcium mobilization. Our data suggest that the mechanism of D(1)R/D(2)R-mediated calcium signaling involves more than receptor-mediated G(q) protein activation, may largely involve downstream signaling pathways, and may not be completely heteromer-specific. In addition, SKF83959 may not exhibit selective activation of D(1)-D(2) heteromers, and its significant cross-reactivity to other receptors warrants careful interpretation of its use in vivo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23680635      PMCID: PMC3716318          DOI: 10.1124/mol.113.085175

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  70 in total

1.  Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects.

Authors:  Lin Pei; Shupeng Li; Min Wang; Mustansir Diwan; Hymie Anisman; Paul J Fletcher; José N Nobrega; Fang Liu
Journal:  Nat Med       Date:  2010-11-28       Impact factor: 53.440

2.  The paradoxical effects of SKF83959, a novel dopamine D1-like receptor agonist, in the rat acoustic startle reflex paradigm.

Authors:  Zhang-Jin Zhang; Xiao-Long Jiang; Steven E Zhang; Christopher J Hough; He Li; Jian-Guo Chen; Xue-Chu Zhen
Journal:  Neurosci Lett       Date:  2005-03-17       Impact factor: 3.046

Review 3.  Heterodimerization of g protein-coupled receptors: specificity and functional significance.

Authors:  Steven C Prinster; Chris Hague; Randy A Hall
Journal:  Pharmacol Rev       Date:  2005-09       Impact factor: 25.468

4.  Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation.

Authors:  F J Monsma; L C Mahan; L D McVittie; C R Gerfen; D R Sibley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Signaling pathways leading to phosphorylation of Akt and GSK-3β by activation of cloned human and rat cerebral D₂and D₃ receptors.

Authors:  Clotilde Mannoury la Cour; Marie-Josèphe Salles; Valérie Pasteau; Mark J Millan
Journal:  Mol Pharmacol       Date:  2010-10-15       Impact factor: 4.436

Review 6.  Lipid rafts, cholesterol, and the brain.

Authors:  Zeljka Korade; Anne K Kenworthy
Journal:  Neuropharmacology       Date:  2008-03-14       Impact factor: 5.250

7.  The D2S and D2L dopamine receptor isoforms are differentially regulated in Chinese hamster ovary cells.

Authors:  L J Zhang; J E Lachowicz; D R Sibley
Journal:  Mol Pharmacol       Date:  1994-05       Impact factor: 4.436

8.  Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal.

Authors:  Samuel P Lee; Christopher H So; Asim J Rashid; George Varghese; Regina Cheng; A José Lança; Brian F O'Dowd; Susan R George
Journal:  J Biol Chem       Date:  2004-05-24       Impact factor: 5.157

9.  Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene.

Authors:  C Le Moine; E Normand; B Bloch
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

10.  Dopamine D1-D2 receptor heteromer in dual phenotype GABA/glutamate-coexpressing striatal medium spiny neurons: regulation of BDNF, GAD67 and VGLUT1/2.

Authors:  Melissa L Perreault; Theresa Fan; Mohammed Alijaniaram; Brian F O'Dowd; Susan R George
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

View more
  35 in total

1.  Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.

Authors:  Jennie L Conroy; R Benjamin Free; David R Sibley
Journal:  ACS Chem Neurosci       Date:  2015-02-20       Impact factor: 4.418

2.  The role of catecholamines in HIV neuropathogenesis.

Authors:  R Nolan; P J Gaskill
Journal:  Brain Res       Date:  2018-04-27       Impact factor: 3.252

3.  Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor.

Authors:  R Benjamin Free; Lani S Chun; Amy E Moritz; Brittney N Miller; Trevor B Doyle; Jennie L Conroy; Adrian Padron; Julie A Meade; Jingbo Xiao; Xin Hu; Andrés E Dulcey; Yang Han; Lihua Duan; Steve Titus; Melanie Bryant-Genevier; Elena Barnaeva; Marc Ferrer; Jonathan A Javitch; Thijs Beuming; Lei Shi; Noel T Southall; Juan J Marugan; David R Sibley
Journal:  Mol Pharmacol       Date:  2014-04-22       Impact factor: 4.436

Review 4.  Dopamine receptors - IUPHAR Review 13.

Authors:  Jean-Martin Beaulieu; Stefano Espinoza; Raul R Gainetdinov
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

5.  Identification of Positive Allosteric Modulators of the D1 Dopamine Receptor That Act at Diverse Binding Sites.

Authors:  Kathryn D Luderman; Jennie L Conroy; R Benjamin Free; Noel Southall; Marc Ferrer; Marta Sanchez-Soto; Amy E Moritz; Blair K A Willette; Tim J Fyfe; Prashi Jain; Steve Titus; Lisa A Hazelwood; Jeffrey Aubé; J Robert Lane; Kevin J Frankowski; David R Sibley
Journal:  Mol Pharmacol       Date:  2018-08-01       Impact factor: 4.436

6.  Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R).

Authors:  Vivek Kumar; Amy E Moritz; Thomas M Keck; Alessandro Bonifazi; Michael P Ellenberger; Christopher D Sibley; R Benjamin Free; Lei Shi; J Robert Lane; David R Sibley; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-02-10       Impact factor: 7.446

7.  Frontline Science: D1 dopaminergic receptor signaling activates the AMPK-bioenergetic pathway in macrophages and alveolar epithelial cells and reduces endotoxin-induced ALI.

Authors:  Nathaniel B Bone; Zhongyu Liu; Jean-Francois Pittet; Jaroslaw W Zmijewski
Journal:  J Leukoc Biol       Date:  2016-10-12       Impact factor: 4.962

8.  A peptide targeting an interaction interface disrupts the dopamine D1-D2 receptor heteromer to block signaling and function in vitro and in vivo: effective selective antagonism.

Authors:  Ahmed Hasbi; Melissa L Perreault; Maurice Y F Shen; Lucia Zhang; Ryan To; Theresa Fan; Tuan Nguyen; Xiaodong Ji; Brian F O'Dowd; Susan R George
Journal:  FASEB J       Date:  2014-07-25       Impact factor: 5.191

Review 9.  G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives.

Authors:  Sergi Ferré; Vicent Casadó; Lakshmi A Devi; Marta Filizola; Ralf Jockers; Martin J Lohse; Graeme Milligan; Jean-Philippe Pin; Xavier Guitart
Journal:  Pharmacol Rev       Date:  2014-02-10       Impact factor: 25.468

10.  (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling.

Authors:  Julie A Meade; R Benjamin Free; Nicole R Miller; Lani S Chun; Trevor B Doyle; Amy E Moritz; Jennie L Conroy; Val J Watts; David R Sibley
Journal:  Psychopharmacology (Berl)       Date:  2014-09-18       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.